Huaren Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Huaren Pharmaceutical Co Ltd working capital to net assets ratio. Huaren Pharmaceutical Co Ltd (300110) has a Working Capital to Net Assets ratio of -26.2% as of March 2026. Working capital of CN¥-242.62 Million (current assets of CN¥1.11 Billion minus current liabilities of CN¥1.35 Billion) is measured against net assets of CN¥925.86 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Huaren Pharmaceutical Co Ltd (300110) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Huaren Pharmaceutical Co Ltd (2007–2025)
Working capital to net assets ratio of Huaren Pharmaceutical Co Ltd from 2007 to 2025. This chart shows how Huaren Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at -26.2%, reflecting working capital of CN¥-242.62 Million against net assets of CN¥925.86 Million CNY. See how many days can Huaren Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Huaren Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2007–2025)
Huaren Pharmaceutical Co Ltd working capital to net assets ratio by year from 2007 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Huaren Pharmaceutical Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Huaren Pharmaceutical Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -52.9% | CN¥-480.66 Million | CN¥909.06 Million | CN¥993.88 Million | CN¥1.47 Billion | ▼ -26.6 pp |
| 2024 | -26.3% | CN¥-361.65 Million | CN¥1.37 Billion | CN¥1.18 Billion | CN¥1.55 Billion | ▼ -72.4 pp |
| 2023 | 46.1% | CN¥1.28 Billion | CN¥2.77 Billion | CN¥2.79 Billion | CN¥1.52 Billion | ▲ +19.2 pp |
| 2022 | 26.9% | CN¥700.13 Million | CN¥2.60 Billion | CN¥2.73 Billion | CN¥2.03 Billion | ▲ +5.8 pp |
| 2021 | 21.2% | CN¥517.09 Million | CN¥2.44 Billion | CN¥3.11 Billion | CN¥2.59 Billion | ▼ -2.1 pp |
| 2020 | 23.3% | CN¥541.69 Million | CN¥2.33 Billion | CN¥1.60 Billion | CN¥1.06 Billion | ▼ -16.2 pp |
| 2019 | 39.4% | CN¥886.11 Million | CN¥2.25 Billion | CN¥1.32 Billion | CN¥430.56 Million | ▲ +4.7 pp |
| 2018 | 34.7% | CN¥781.80 Million | CN¥2.25 Billion | CN¥1.63 Billion | CN¥847.90 Million | ▲ +27.5 pp |
| 2017 | 7.2% | CN¥112.13 Million | CN¥1.55 Billion | CN¥1.27 Billion | CN¥1.16 Billion | ▲ +6.9 pp |
| 2016 | 0.3% | CN¥5.34 Million | CN¥1.53 Billion | CN¥1.04 Billion | CN¥1.04 Billion | ▲ +8.5 pp |
| 2015 | -8.1% | CN¥-116.73 Million | CN¥1.44 Billion | CN¥1.15 Billion | CN¥1.27 Billion | ▼ -4.3 pp |
| 2014 | -3.8% | CN¥-56.79 Million | CN¥1.48 Billion | CN¥1.06 Billion | CN¥1.12 Billion | ▼ -16.1 pp |
| 2013 | 12.2% | CN¥178.61 Million | CN¥1.46 Billion | CN¥1.06 Billion | CN¥877.42 Million | ▼ -0.5 pp |
| 2012 | 12.7% | CN¥170.69 Million | CN¥1.34 Billion | CN¥584.00 Million | CN¥413.31 Million | ▼ -37.6 pp |
| 2011 | 50.4% | CN¥600.30 Million | CN¥1.19 Billion | CN¥646.07 Million | CN¥45.77 Million | ▼ -12.0 pp |
| 2010 | 62.3% | CN¥688.23 Million | CN¥1.10 Billion | CN¥735.83 Million | CN¥47.60 Million | ▲ +59.3 pp |
| 2009 | 3.1% | CN¥9.64 Million | CN¥313.80 Million | CN¥271.62 Million | CN¥261.98 Million | ▲ +5.9 pp |
| 2008 | -2.9% | CN¥-6.35 Million | CN¥221.03 Million | CN¥199.59 Million | CN¥205.94 Million | ▲ +4.7 pp |
| 2007 | -7.6% | CN¥-14.00 Million | CN¥184.68 Million | CN¥162.50 Million | CN¥176.50 Million | — |